Steven J. Altschuler

Sep 17, 2024 | nature.com | Xiaoxiao Sun |Steven J. Altschuler

AbstractDisease relapse driven by acquired drug resistance limits the effectiveness of most systemic anti-cancer agents. Targeting persistent cancer cells in residual disease before relapse has emerged as a potential strategy for enhancing the efficacy and the durability of current therapies. However, barriers remain to implementing persister-directed approaches in the clinic.